INTASYL™ self-delivering RNAi therapy specifically dual-targeting BRD4 and PD-1 elicits complete tumor responses and evidence of synergy in a subcutaneous Hepa1-6 model of murine hepatoma in C57BL/6N mice.

Journal of Clinical Oncology, 2021, Volume 39, Supplement 15. doi: 10.1200/JCO.2021.39.15_suppl.e14537.  Benjamin Cuiffo, Melissa Maxwell, Dingxue Yan, Brianna Rivest, James Cardia and Simon P. Fricker.